Anti-D Immunoglobulin
WinRho® SDF is the first Anti-D Immunoglobulin approved for use in ITP. It is derived from human plasma (the liquid portion of blood) and is specially prepared to have high levels of a specific antibody, Anti-D. Currently it is thought that this antibody prevents the destruction of platelets in the spleen.
Anti-D immunoglobulin (WinRho® SDF) is given by a 3-5 minute infusion into a vein.
Please see full Prescribing Information.
Anti-D may help raise the platelet level for 1-3 months after each infusion1. Periodic infusions of Anti-D may allow patients to achieve stable platelet counts.2
Side effects sometimes occur and may include:
- Mild anemia
- Headache
- Fever
- Chills
Other possible side effects may include back pain, shaking chills, dark colored or discolored urine, decreased urine production, swelling or shortness of breath.3 Please contact your physician promptly if you experience these symptoms.
Please see Important Safety Information.
Anti-D Immunoglobulin is only effective in Rh-positive patients and in patients whose spleen has not been removed.
Because Anti-D Immunoglobulin is made from human plasma, special processes are used in the preparation of WinRho® SDF to safeguard against known viruses that may be found in human blood. However, the potential to transmit infectious agents cannot be totally eliminated.
- Data on file. Cangene Corporation. Baxter Healthcare Corporation.
- Sandler S.G. and Tutuncuoglu S.O. Immune Thrombocytopenic Purpura -- current management practices. Expert Opin Pharmacother. 2004; 5(12): 2515-2527.
- WinRho® SDF. [Rho(D) Immune Globulin Intravenous (Human)] package insert, Cangene Corporation, Winnipeg, Canada, Baxter Healthcare Corporation, Westlake Village, CA, USA, April 2006.
